Akshay Naheta
Partner, EMEA @ SoftBank Vision Fund
London, United Kingdom
Akshay Naheta is a Series A investor at SoftBank Vision Fund in London focused on Automotive and Autonomous Vehicles. Akshay Naheta - Managing Director @ SoftBank
- Total investments:
- 11
- Last investment:
- Lead investor:
- 82%
Last updated:
For AI agents: llms.txt
Industries Akshay Naheta invests in
Stages Akshay Naheta invests in
Countries Akshay Naheta invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Automotive 4 (36%)
- Autonomous Vehicles 4 (36%)
- Biotechnology 3 (27%)
- Genetics 2 (18%)
- Military 2 (18%)
Stage
- Series A 3 (27%)
- Post-IPO Debt 2 (18%)
- Series D 1 (9%)
- Series F 1 (9%)
- Series G 1 (9%)
Country
- United States 8 (73%)
- Germany 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Robotic Research, LLC, is a small engineering firm founded by Alberto Lacaze and Karl Murphy in 2002. Both worked together in the Intelligent Systems Division of the National Institute of Standards and Technology (Gaithersburg, MD) when they decided to make the move (across the street as it turned out) to pursue focused interest in unmannedvehicles. | $228M / Series A / Dec 09, 2021 | ||
| Forterra provides autonomous systems for ground-based movement in the working world. The company is among the earliest innovators in driverless technology, focused on building systems that protect front-line soldiers and enable civilian workers in our industrial base. Forterra is a go-to provider of autonomous solutions for the U.S. Department ofDefense, which harnesses autonomy for asymmetric warfare in critical conditions. | $243M / Series A / Dec 09, 2021 | ||
| Forterra delivers autonomous mission systems for defense. From self-driving land systems to coordinated swarms of robotic platforms, the company builds scalable, robust, mission-critical hardware and software designed to empower customers to deploy autonomy as a force multiplier - extending reach, survivability, and effectiveness across thebattlespace and industrial domains. | $243M / Series A / Dec 09, 2021 | ||
| Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, fasterturnaround time, and a lower price than most single-gene diagnostic tests today.What’s our plan? It takes three steps:--Make genetic testing more affordable and accessible than ever before.--Build a secure and trusted genome management infrastructure.--Design a new global community for sharing genetic information to advance science and medicine.Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people. | $1.2B / Post-IPO Debt / Apr 05, 2021 | ||
| Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. Pacific Biosciences offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes singlemolecule biochemical reactions in real time. It also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Pacific Biosciences' customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. Joseph Bonventre and Stephen Turner founded Nanofluidics in 2000 that laterbecame Pacific Biosciences. Its headquarters is in Menlo Park in California. | $900M / Post-IPO Debt / Feb 10, 2021 | ||
| AUTO1 Group is a used-car marketplace with its own certified and diversified inventory and a technology platform that allows buyers and sellers.AUTO1 is aimed primarily at the used car trade. By connecting buyers and sellers through technology the company enables consumers as well as dealers to trade seamlessly. Sourcing from all channelsincluding OEMs and dealerships. AUTO1 Group owns business units like AUTO1.com, Autohero.com or wirkaufendeinauto.de. AUTO1 Group operates in almost 30 countries and continues to expand rapidly. | $302.7M / Convertible Note / Jul 30, 2020 | ||
| C2FO provides a platform with many dynamic tools to help manage businesses' accounts payable and accounts receivable on-demand. C2FO is the first working capital market in the world. Their ability to create a seamless match between A/R and A/P has enabled efficiency in the riskless provisioning of working capital between suppliersand buyers. Finally, suppliers can take control of their cash flow while buyers can increase EBITDA and gross margin and earn a better return on short-term cash while improving the financial health of their supply chains. | $200M / Series G / Aug 07, 2019 | ||
| Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates.Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech andhealthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines. | $200M / Private Equity / Nov 13, 2018 | ||
| Light enables machines to see like humans using a camera-based perception platform that revolutionizes perception for ADAS/AV. | $121M / Series D / Jul 18, 2018 | ||
| AUTO1 Group is a used-car marketplace with its own certified and diversified inventory and a technology platform that allows buyers and sellers.AUTO1 is aimed primarily at the used car trade. By connecting buyers and sellers through technology the company enables consumers as well as dealers to trade seamlessly. Sourcing from all channelsincluding OEMs and dealerships. AUTO1 Group owns business units like AUTO1.com, Autohero.com or wirkaufendeinauto.de. AUTO1 Group operates in almost 30 countries and continues to expand rapidly. | $564.3M / Series F / Jan 15, 2018 | ||
| See all 11 investments → | |||
Co-Investors
About SoftBank Vision Fund
SoftBank Vision Fund is a subsidiary of Softbank Group that specializes in growth capital and social impact investments. Sectors that the fund invests in include the internet of things, artificial intelligence (AI), robotics, communications infrastructure, telecoms, computational biology, biotech, cloud technologies and software, consumer internetbusinesses, financial technology, and mobile apps. The Fund is designed to be a catalyst for technology progress in anticipation that it will expand SoftBank's capabilities, accelerating progress towards SoftBank 2.0.It aims to invest in businesses and foundational platforms that SoftBank believes to revolutionize and innovate the world tomorrow.
SoftBank Vision Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Colin Fan
Managing Partner, Americas, Asia
|
|||
David Thevenon
Partner
|
|||
Javier Villamizar
Partner, Joint Ventures and Portfolio Synergies
|
|||
Sumer Juneja
Partner and Head of India
|
|||
|
Akshay Naheta
Partner, EMEA
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Akshay Naheta invest in?
Akshay Naheta invests primarily in Automotive, Autonomous Vehicles and Biotechnology startups, most often at Series A and Post-IPO Debt stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Akshay Naheta?
Public channels for Akshay Naheta include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Akshay Naheta last invest?
The most recent investment recorded for Akshay Naheta closed in Dec 2021. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
